论文部分内容阅读
目的研究布拉酵母菌散对肝硬化大鼠肠黏膜屏障的保护作用及其可能机制。方法采用皮下注射40%CCL4橄榄油溶液+10%酒精饮料诱导肝硬化模型。造模成功后,治疗组用布拉酵母菌灌胃[75×108CFU/(kg·d)],对照组、模型组给予等容量的生理盐水灌胃,连续14 d。采用鲎试剂终点显色法检测血浆内毒素水平,应用分光光度法测定小肠组织二胺氧化酶(DAO)活性,应用自动生化分析仪检测血清丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)变化。结果模型组血浆内毒素水平[(0.251±0.011)EU/m L]较治疗组[(0.168±0.012)EU/m L]明显升高,差异有统计学意义(P<0.01);模型组肠组织DAO活性为(0.432±0.074)U/mg,明显较对照组[(0.728±0.065)U/mg]降低,差异有统计学意义(P<0.01),治疗组DAO活性为(0.548±0.053)U/mg,与模型组相比较,肠DAO活性升高,差异有统计学意义(P<0.01),模型组、治疗组肠组织DAO活性较对照组明显降低(P<0.01);模型组血清ALT、AST含量分别为(133.89±8.09)U/m L、(176.92±10.94)U/m L,比对照组ALT、AST含量[(36.73±6.95)U/m L、(41.35±10.07)U/m L]明显升高,P<0.01;治疗组[(95.76±7.27)U/m L、(158.02±5.94)U/m L]与模型组相比较,ALT、AST含量下降,差异有统计学意义(P<0.01)。结论肝硬化大鼠存在肠黏膜屏障受损,布拉酵母菌可通过调整肠道菌群,改善肠源性内毒素血症,对肠黏膜屏障起到保护作用,可作为慢性肝病的辅助治疗。
Objective To study the protective effect of Bram yeast on intestinal mucosal barrier in cirrhotic rats and its possible mechanism. Methods The model of liver cirrhosis was induced by subcutaneous injection of 40% CCL4 olive oil solution and 10% alcoholic beverage. After successful modeling, the treatment group was administered with Saccharomyces cerevisiae [75 × 108CFU / (kg · d)], and the control group and model group were given normal saline for 14 days. Plasma endotoxin levels were determined by the colorimetric assay of 鲎 reagent. The activity of diamine oxidase (DAO) in small intestine was measured by spectrophotometry. Serum alanine aminotransferase (ALT), aspartate Aminotransferase (AST) changes. Results The level of plasma endotoxin [(0.251 ± 0.011) EU / m L] in model group was significantly higher than that in the treatment group [(0.168 ± 0.012) EU / m L], the difference was statistically significant The DAO activity in the treatment group was (0.432 ± 0.074) U / mg, which was significantly lower than that in the control group [(0.728 ± 0.065) U / mg], the difference was statistically significant (P <0.01). Compared with the model group, the activity of DAO in the model group and the treatment group was significantly lower than that in the control group (P <0.01). Compared with the model group, the DAO activity in the model group was significantly increased The levels of ALT and AST were (133.89 ± 8.09) U / m L and (176.92 ± 10.94) U / m L, respectively, which were significantly higher than those of the control group (36.73 ± 6.95 U / m L, 41.35 ± 10.07 U / m L], P <0.01; compared with the model group, the levels of ALT and AST in the treatment group [(95.76 ± 7.27) U / m L, (158.02 ± 5.94) U / m L] Significance (P <0.01). Conclusion The intestinal mucosal barrier is impaired in rats with cirrhosis. Saccharomyces boulardii can improve gut-derived endotoxemia by regulating the intestinal flora and play a protective role in the intestinal mucosal barrier, which can be used as adjuvant therapy for chronic liver disease.